Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F McLeod

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Diabetes Care|February 24, 2001
Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placeboJ B Kalbag, Y H Walter, J R Nedelman, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitusL Keilson, S Mather, Y H Walter, et al.
Endocrinology|May 1, 1987
Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentaeJ E Nestler, J F McLeod, M A Kowalski, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1993
Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutationJ F McLeod, L Kovács, M B Gaskill, et al.
British Journal of Clinical Pharmacology|January 3, 2001
Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjectsH Zhou, T L Chen, M Marino, et al.
Journal of Clinical Pharmacology|October 5, 2001
The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjectsH Zhou, A Horowitz, P C Ledford, et al.
British Journal of Anaesthesia|July 4, 2014
GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteersJ F McLeod, J M Leempoels, S X Peng, et al.
Journal of Clinical Pharmacology|September 3, 1999
Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)H Zhou, S Khalilieh, H Lau, et al.
Clinical Pharmacology and Therapeutics|February 5, 2010
Proof of concept: a PhRMA position paper with recommendations for best practiceM E Cartwright, S Cohen, J C Fleishaker, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjectsT Chen, T F Miller, P Prasad, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Diabetes Care|February 24, 2001
Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placeboJ B Kalbag, Y H Walter, J R Nedelman, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitusL Keilson, S Mather, Y H Walter, et al.
Endocrinology|May 1, 1987
Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentaeJ E Nestler, J F McLeod, M A Kowalski, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1993
Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutationJ F McLeod, L Kovács, M B Gaskill, et al.
British Journal of Clinical Pharmacology|January 3, 2001
Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjectsH Zhou, T L Chen, M Marino, et al.
Journal of Clinical Pharmacology|October 5, 2001
The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjectsH Zhou, A Horowitz, P C Ledford, et al.
British Journal of Anaesthesia|July 4, 2014
GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteersJ F McLeod, J M Leempoels, S X Peng, et al.
Journal of Clinical Pharmacology|September 3, 1999
Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)H Zhou, S Khalilieh, H Lau, et al.
Clinical Pharmacology and Therapeutics|February 5, 2010
Proof of concept: a PhRMA position paper with recommendations for best practiceM E Cartwright, S Cohen, J C Fleishaker, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjectsT Chen, T F Miller, P Prasad, et al.
Pageof 3